MedTrace Logo

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

NCT02457845 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-01-19

No results posted yet for this study

Summary

This study is a clinical trial to determine the safety of injecting G207 (a new experimental virus therapy) into a recurrent or progressive brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication and tumor cell killing, will also be tested.

Conditions

  • Supratentorial Neoplasms, Malignant
  • Malignant Glioma
  • Glioblastoma
  • Anaplastic Astrocytoma
  • PNET
  • Cerebral Primitive Neuroectodermal Tumor
  • Embryonal Tumor

Interventions

BIOLOGICAL

G207

Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI

Sponsors & Collaborators

  • Food and Drug Administration (FDA)

    collaborator FED

  • National Center for Advancing Translational Sciences of the National Institutes of Health

    collaborator UNKNOWN

  • Cannonball Kids' Cancer Foundation

    collaborator OTHER

  • Rally Foundation for Childhood Cancer Research

    collaborator OTHER

  • Hyundai Hope On Wheels

    collaborator OTHER

  • St. Baldrick's Foundation

    collaborator OTHER

  • United States Department of Defense

    collaborator FED

  • The Andrew McDonough B+ Foundation

    collaborator OTHER

  • Kaul Pediatric Research Institute

    collaborator UNKNOWN

  • University of Alabama at Birmingham

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    collaborator OTHER

  • Kelsie's Crew

    collaborator UNKNOWN

  • Eli's Block Party Childhood Cancer Foundation

    collaborator UNKNOWN

  • Eli Jackson Foundation

    collaborator UNKNOWN

  • Jaxon's F.R.O.G. Foundation

    collaborator UNKNOWN

  • Battle for a Cure Foundation

    collaborator UNKNOWN

  • Sandcastle Kids

    collaborator UNKNOWN

  • Gregory K. Friedman, MD

    lead OTHER

Principal Investigators

  • Gregory K Friedman, M.D. · University of Alabama at Birmingham (UAB)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2020-06-30
Completion
2024-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02457845 on ClinicalTrials.gov